Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer |
Yoo, Changhoon
(Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)
Han, Boram (Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine) Kim, Hyeong Su (Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine) Kim, Kyu-pyo (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Kim, Deokhoon (Asan Institute for Life Science, University of Ulsan College of Medicine) Jeong, Jae Ho (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Lee, Jae-Lyun (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Kim, Tae Won (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Kim, Jung Han (Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine) Choi, Dae Ro (Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine) Ha, Hong Il (Department of Radiology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine) Seo, Jinwon (Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine) Chang, Heung-Moon (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Ryoo, Baek-Yeol (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Zang, Dae Young (Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine) |
1 | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30. |
2 | Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH. Prediction of cancer incidence and mortality in Korea, 2017. Cancer Res Treat. 2017;49:306-12. |
3 | Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-4. |
4 | Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273-81. |
5 | Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469-74. |
6 | Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7. |
7 | Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-25. |
8 | Han B, Jung JY, Kim HS, Cho JW, Kim KC, Lim H, et al. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer. Cancer Chemother Pharmacol. 2016;78:949-58. |
9 | Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47. |
10 | Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10. |
11 | Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS, et al. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol. 2017;80:209-15. |
12 | Robertson S, Hyder O, Dodson R, Nayar SK, Poling J, Beierl K, et al. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol. 2013;44:2768-73. |
13 | Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003-10. |
14 | Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9:e115383. |
15 | Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, Ryoo BY, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer. 2017;116:561-7. |